Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 25 March 2025, 11:21 HKT/SGT
Share:
    

Source: Eisai
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace

TOKYO, Mar 25, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Nadeshiko Brand 2025 as a listed company excelling in the promotion of women in the workplace. This marks Eisai’s second consecutive inclusion on the list.

The Nadeshiko Brand initiative aims to introduce certain Tokyo Stock Exchange (TSE)-listed enterprises that are outstanding in terms of encouraging women’s empowerment in the workplace as attractive stocks to investors who place emphasis on improving corporate value in the medium- and long-term, thereby further raising investors' interest in such enterprises and accelerating the initiatives of outstanding enterprises. The initiative has been co-conducted by METI and TSE since FY2012.

Eisai’s Articles of Incorporation defines employees as one of the major stakeholders and specifies that Eisai endeavors to "respecting human rights and diversity," "providing full opportunities for growth in support of self-fulfillment," and "creating an employee-friendly environment" in addition to "ensuring stable employment". In line with this, Eisai has formulated an “Integrated HR Strategy” and been implementing human resource policies with the pillars of “well-being including employee health”, “diverse workstyle”, “employee growth”, and “organizational and business growth”, that ensure both individuals and the organization grow together. DE&I (Diversity, Equity & Inclusion) is placed at the core of all human resource policies, and Eisai has been promoting women’s empowerment as a first step in promoting DE&I in Japan.

In 2021, Eisai formulated a 10-year plan, named "Eisai Diversity & Inclusion 2021," which includes targets for the ratio of women in management positions and the rate of men taking paternity and childcare leave, as well as action plans to achieve these targets.

Eisai is planning and promoting specific and effective measures tailored to the circumstances of each office. Since 2023, Eisai has been publishing the “Human Capital Report” that focuses on its human capital initiatives and KPI linked to its human resource strategies. Furthermore, placing its corporate concept human health care (hhc), which is deeply ingrained in Eisai Group employees, at the heart of DE&I promotion, Eisai has formulated a new global slogan “We see difference, we see potential” in March 2024, and has been working on activities to raise awareness and promote DE&I throughout the Group.

Eisai is seeking to provide impact to various stakeholders by delivering new value to patients and the people in the daily living domain through the activities of our employees who are the only stakeholders that can directly contribute to our hhc corporate concept.

*For further details on Eisai’s human capital strategy, including DE&I promotion, can be found in the annual Value Creation Report, and on the Sustainability page of the corporate website.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Mar 25, 2025 16:28 HKT/SGT
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award
at the 12th Technology Management and Innovation Awards
Mar 10, 2025 19:24 HKT/SGT
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
Mar 5, 2025 08:09 HKT/SGT
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 4, 2025 16:22 HKT/SGT
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 3, 2025 14:41 HKT/SGT
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
Mar 3, 2025 12:53 HKT/SGT
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Feb 28, 2025 11:31 HKT/SGT
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 14, 2025 11:09 HKT/SGT
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 3, 2025 16:23 HKT/SGT
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: